Drug
Ritonavir clinical trials
Also written Norvir, RTV and ABT-538.
- studies test it
- 354
- open now
- 5
- in phase 3
- 71
- first study started
- 1998
Keep track of what changes. Save the Ritonavir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
326 studies that test it; most in 2008 (24)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 5 |
| 2000 | 5 |
| 2001 | 5 |
| 2002 | 6 |
| 2003 | 6 |
| 2004 | 11 |
| 2005 | 18 |
| 2006 | 20 |
| 2007 | 18 |
| 2008 | 24 |
| 2009 | 24 |
| 2010 | 18 |
| 2011 | 22 |
| 2012 | 20 |
| 2013 | 16 |
| 2014 | 18 |
| 2015 | 23 |
| 2016 | 10 |
| 2017 | 6 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 13 |
| 2022 | 10 |
| 2023 | 5 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 141
- Phase 2
- 92
- Phase 3
- 71
- Phase 4
- 45
- No phase
- 18
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 13
Who runs them
Industry 223 · Other 131
Boehringer Ingelheim (29) · Hoffmann-La Roche (26) · AbbVie (22) · National Institute of Allergy and Infectious Diseases (NIAID) (21) · Bristol-Myers Squibb (20) · Pfizer (18) · ViiV Healthcare (16) · GlaxoSmithKline (11)
Often tested with
Tested in the same studies.
Atazanavir (49) · Darunavir (45) · Paritaprevir (40) · Lopinavir (36) · Ombitasvir (33) · Ribavirin (32) · Dasabuvir (29) · Tipranavir (22)
Studies
Open first, then newest update. How each study uses Ritonavir is read from its arms, and is right about nine times in ten.
Testing it · 354
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Ritonavir (RTV)
- STARLITE for Unresectable High-Grade GliomasRecruitingPhase 1University of MiamiNCT06428045Written as Ritonavir
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseaseRecruitingPhase 3PfizerNCT05261139Written as ritonavir
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Hydroxychloroquine + lopinavir/ritonavir
- Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic LeukemiaCompletedPhase 1City of Hope Medical CenterNCT02948283Written as Ritonavir
- Lonafarnib With and Without Ritonavir in HDV (LOWR-1)CompletedPhase 2EIT Pharma, Inc.NCT02430181Written as ritonavir
- Titrating-Dose of Lonafarnib in Combination With RitonavirCompletedPhase 2EIT Pharma, Inc.NCT02527707Written as Ritonavir
- A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19TerminatedPhase 1PfizerNCT05386472Written as ritonavir
- Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT00196625Written as Ritonavir (drug)
- Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast CancerCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06710990Written as Ritonavir
- A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating WomenCompletedPhase 1PfizerNCT05441215Written as ritonavir
- Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus InfectionCompletedPhase 3Soroka University Medical CenterNCT05229991Written as Ritonavir
- Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136CompletedPhase 3French National Agency for Research on AIDS and Viral HepatitisNCT00421551Written as ritonavir
- Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase InhibitorsCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02738502Written as darunavir monotherapy
- Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT00528060Written as Ritonavir
- RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID SymptomsCompletedPhase 2Kanecia Obie ZimmermanNCT05965726Written as Ritonavir
- EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19CompletedPhase 2/3PfizerNCT04960202Written as Ritonavir
- Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet FormulationCompletedPhase 1PfizerNCT05263895Written as PF-07321332/ritonavir
- A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT03593954Written as Ritonavir
See all 354 studies that test Ritonavir →
Given in every arm · 76 — Ritonavir is usual care beside what is tested
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05150691Written as Ritonavir
- Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)CompletedPhase 2EIT Pharma, Inc.NCT02430194Written as ritonavir
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingPhase 2/3Gilead SciencesNCT02016924Written as LPV/r
- Paxlovid for Treatment of Long CovidCompletedPhase 2Stanford UniversityNCT05576662Written as Ritonavir
- Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic InsufficiencyCompletedPhase 1Boehringer IngelheimNCT02249442Written as Ritonavir (r)
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.CompletedPhase 2Harlan M KrumholzNCT05668091Written as Ritonavir
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01400412Written as Ritonavir
- A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/RitonavirCompletedPhase 2PfizerNCT05567952Written as ritonavir
- Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCTerminatedPhase 3Bristol-Myers SquibbNCT01620944Written as Ritonavir
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneWithdrawnPhase 3Bristol-Myers SquibbNCT01605084Written as Ritonavir
- Study of DS-8201a for Participants With Advanced Solid Malignant TumorsCompletedPhase 1Daiichi Sankyo Co., Ltd.NCT03383692Written as Ritonavir
- Dual Therapy With Boosted Darunavir + DolutegravirCompletedPhase 3Technical University of MunichNCT02486133Written as Norvir
- Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownPhase 4Kirby InstituteNCT03017872Written as Ritonavir
- A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19WithdrawnPhase 2PfizerNCT05545319Written as Ritonavir
- Study of PBI-0451 in Healthy Subjects.CompletedPhase 1Pardes Biosciences, Inc.NCT05011812Written as Ritonavir
- Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and AdolescentsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00006604Written as Ritonavir
- Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00051831Written as Ritonavir
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent GlioblastomaCompletedPhase 1/2University of UlmNCT02770378Written as Ritonavir
- Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19Status unknownNot applicableGrupo de Investigación Clínica en Oncología RadioterapiaNCT04380818Written as Ritonavir/lopinavir
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b InfectionCompletedPhase 3AbbVie (prior sponsor, Abbott)NCT01767116Written as ABT-450/r/ABT-267, ABT-333
Showing 20 of 76.
As the comparator · 21 — what is tested is compared with Ritonavir
- Ndovu RCT: Investing the Optimal Management of Dolutegravir ResistanceRecruitingPhase 3University of NairobiNCT06747507Written as Darunavir+Ritonavir
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnPhase 4Juan A. ArnaizNCT02470650Written as Ritonavir
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT02275780Written as Ritonavir
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)CompletedPhase 3ViiV HealthcareNCT01910402Written as Ritonavir
- A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 InfectionStatus unknownPhase 4Shandong Provincial HospitalNCT05697055Written as Nirmatrelvir-Ritonavir
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsCompletedPhase 3Gilead SciencesNCT01815736Written as RTV
- Pharmacokinetic Study of Posaconazole Boosted FosamprenavirCompletedPhase 1Radboud University Medical CenterNCT00817765Written as Ritonavir
- Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected WomenCompletedPhase 3Gilead SciencesNCT02652624Written as RTV
- Efavirenz and Ritonavir on Human Brain P-GlycoproteinCompletedPhase 1/2Washington University School of MedicineNCT01668147Written as Oral ritonavir
- A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)CompletedPhase 3University of Modena and Reggio EmiliaNCT01900106Written as abacavir/lamivudine + darunavir/ritonavir
- Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02116660Written as Ritonavir
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedPhase 2ViiV HealthcareNCT01384734Written as Ritonavir 100 mg
- Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsCompletedPhase 3ViiV HealthcareNCT01449929Written as ritonavir 100mg OAD
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsCompletedPhase 3Gilead SciencesNCT01475838Written as RTV
- Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01108510Written as RTV
- Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 2Gilead SciencesNCT00892437Written as RTV
- Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral DensityCompletedPhase 3Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT01966822Written as Protease Inhibitor/ritonavir
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsCompletedPhase 3Gilead SciencesNCT01106586Written as Ritonavir
- Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 InfectionStatus unknownPhase 3Peking Union Medical CollegeNCT02219672Written as Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir
- A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)CompletedPhase 4ViiV HealthcareNCT01102972Written as Reyataz + Norvir + Truvada
Showing 20 of 21.
Codes
What other systems call Ritonavir · ClinicalTrials.gg INT008705
- MeSH (NLM) D019438RitonavirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) O3J8G9O825RITONAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 85762Confirmed FDA, Wikidata
- Wikidata Q422618ritonavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1609RitonavirOne source FDA
- DrugBank DB00503One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D019438 | Ritonavir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | O3J8G9O825 | RITONAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 85762 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422618 | ritonavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1609 | Ritonavir | One source FDA |
| DrugBank | DB00503 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.